Short answer
NovoCure Ltd (NVCR) filed an 8-K current report with the SEC on June 18, 2026 reporting Item 7.01 (Regulation FD Disclosure). Phase 3 TRIDENT missed its primary overall-survival endpoint for earlier TTFields initiation in newly diagnosed GBM.
NovoCure Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Phase 3 TRIDENT missed its primary overall-survival endpoint for earlier TTFields initiation in newly diagnosed GBM
- Median overall survival 17.7 months Early Start vs 17.5 months Maintenance Start
- Hazard ratio 0.953 with p=0.519, indicating no statistically significant treatment-timing benefit
- No new safety signals; TTFields remained well-tolerated with device safety consistent with prior studies
- Results accepted for presentation at ASTRO 2026, supporting further clinical scrutiny but weakening early-initiation expansion prospects
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NovoCure Ltd 8-K filings
Get the next NVCR 8-K as it lands
Follow NVCR for push alerts, or ask the research agent what this filing means.